Bridge™

 

Drug-free Opioid Withdrawal Device

Masimo - Bridge product and application

Don’t let the fear of withdrawal symptoms be a barrier to your patients' progress during treatment.

Bridge helps significantly reduce opioid withdrawal symptoms.

Bridge is the first FDA-cleared, drug-free, non-surgical device to use neuromodulation to aid in the reduction of symptoms associated with opioid withdrawal.

In a study of 73 adult patients with opioid use disorder, a reduction in opioid withdrawal symptoms was observed when Bridge was used during active withdrawal. The study demonstrated Bridge to be:

Fast

 

Provides symptom relief beginning in as little as 20 minutes1

Down arrow

Effective

 

May significantly reduce opioid withdrawal symptoms

Help users successfully progress in treatment:

  • 88% of patients successfully transitioned into a medically assisted therapy (MAT) program.1

Down arrow

Safe2

 
  • No reported side effects with minimal risks during device placement
  • 0.17% Incidence of significant pain at the lead implantation site
  • 0.91% Incidence of bleeding at the lead implantation site
  • 0.91% Incidence of dermatitis at the lead implantation site
  • 0% Incidence of syncope

What is Bridge?

 

Bridge is a small electrical nerve stimulator device that contains a battery-powered chip and wires that are applied around a patient's ear. It requires a prescription and is offered to qualified healthcare professionals with training. Bridge includes a kit containing everything required to apply the device.

Masimo - Bridge application on ear with image call outs and brain illustration with call outs

Who Can Bridge Help?

Bridge can be used for patients* experiencing opioid withdrawal symptoms, while undergoing treatment for opioid use disorder when:

  • Initiating treatment
  • Transitioning to naltrexone
  • Tapering off medication-assisted treatment

References:

  1. *Contraindications: Use of cardiac pacemakers, Hemophilia, Psoriasis vulgaris

  2. 1Miranda A, Taca A. Neuromodulation with percutaneous electrical nerve field stimulation is associated with reduction in signs and symptoms of opioid withdrawal: a multisite, retrospective assessment [published correction appears in Am J Drug Alcohol Abuse. 2018;44(4):498]. Am J Drug Alcohol Abuse. 2018;44(1):56‐63. doi:10.1080/00952990.2017.1295459

  3. 2Roberts, Arthur et al. “Minimal adverse effects profile following implantation of periauricular percutaneous electrical nerve field stimulators: a retrospective cohort study.” Medical devices (Auckland, N.Z.) vol. 9 389-393. 3 Nov. 2016, doi:10.2147/MDER.S107426Roberts, Arthur et al. “Minimal adverse effects profile following implantation of periauricular percutaneous electrical nerve field stimulators: a retrospective cohort study.” Medical devices (Auckland, N.Z.) vol. 9 389-393. 3 Nov. 2016, doi:10.2147/MDER.S107426.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.

PLCO-004237/PLM-12507B-0820